RECIBOKIBART produced rapid improvements in pustular and overall disease severity among patients with acute flares of generalised pustular psoriasis (GPP) in a phase 2 randomised trial.
The multicentre, double-blind, placebo-controlled trial conducted in China included 33 patients with moderate-to-severe acute GPP. Patients were randomly assigned 2:1 to receive a single intravenous dose of recibokibart 1050 mg or placebo on day 1.
The primary endpoint was achievement of a Generalised Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 or 1 at week 1.
At day 8, 86.4% of patients receiving recibokibart achieved the primary endpoint compared with 9.1% receiving placebo (between-group difference: 77.3%; 95% CI: 42.5–88.9; P<0.0001).
Recibokibart also produced greater improvements across key secondary endpoints. A GPPGA total score of 0 or 1 was achieved by 63.6% of patients receiving recibokibart versus 0% receiving placebo, while complete pustule clearance occurred in 54.5% versus 0%, respectively.
Mean percentage change from baseline in the Generalised Pustular Psoriasis Area and Severity Index (GPPASI) was −59.3% with recibokibart compared with 0% with placebo at week 1.
By week 4, 72.7% of patients treated with recibokibart achieved GPPASI 75.
Clinical improvements were observed as early as 24 hours after treatment and were maintained through week 12. However, assessments after day 8 included patients who received open-label recibokibart, limiting interpretation of longer-term comparisons with placebo.
These findings highlight the potential for rapid disease control in patients experiencing acute GPP flares, an area where prompt treatment is particularly important.
The most frequently reported adverse events were hypoproteinaemia, hypertriglyceridaemia, hyperlipidaemia, and pruritus. Overall, the treatment demonstrated an acceptable safety profile.
The findings suggest that targeting the interleukin-36 receptor with a single intravenous dose of recibokibart may provide rapid control of acute GPP flares, with substantial improvements in pustulation and overall disease severity observed within the first week.
Reference
Yang B et al. Efficacy and safety of recibokibart, an interleukin-36 receptor antibody, in generalized pustular psoriasis: a phase 2 randomized trial. Br J Dermatol. 2026;DOI: 10.1093/bjd/ljag369.
Featured image: ShunTerra on Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
